A comparative study of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in the detection of intrahepatic lesion
- PMID: 36086711
- PMCID: PMC10980474
- DOI: 10.1097/MD.0000000000030482
A comparative study of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in the detection of intrahepatic lesion
Abstract
We evaluated the diagnostic performance of both gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI) and contrast-enhanced ultrasound (CEUS) for focal liver lesions, especially for the detection of small (<2 cm) intrahepatic lesions. We retrospectively reviewed patients who underwent Gd-EOB-DTPA-MRI and CEUS before liver resection and compared Gd-EOB-DTPA-MRI and CEUS in the detection of focal liver lesions. A total of 216 patients were included, and 309 lesions were found. The sensitivity values of MRI and CEUS for the main lesion were both more than 95%, and the coincidence rates were both more than 80%. Regarding lesions <2 cm, 135 such lesions were detected by MRI, whereas only 85 were detected by CEUS. For lesions <2 cm, the sensitivity, specificity, and coincidence rates of MRI were significantly better than those of CEUS. Among 27 patients, 50 more lesions were detected by MRI than CEUS, 56% (28/50) of which were malignant. For the large lesion, the diagnostic performance is similar between Gd-EOB-DTPA-MRI and CEUS, and the sensitivity and coincidence rates of both methods are high. Gd-EOB-DTPA-MRI is likely to detect small (<2 cm) focal intrahepatic lesions.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
References
-
- Battaglia V, Cervelli R. Liver investigations: updating on US technique and contrast-enhanced ultrasound (CEUS). Eur J Radiol. 2017;96:65–73. - PubMed
-
- Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80. - PubMed
-
- Pascolo L, Cupelli F, Anelli PL, et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun. 1999;257:746–52. - PubMed
-
- Son J, Hwang SH, Park S, et al. Imaging features of hepatocellular carcinoma: quantitative and qualitative comparison between MRI-enhanced with Gd-EOB-DTPA and Gd-DTPA. Invest Radiol. 2019;54:494–9. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
